Takeda Pharmaceutical, through Takeda America Holdings, agreed to acquire Inviragen for $35 million in cash plus $215 million in potential milestone fees contingent on the progress of the firm's infectious-disease vaccines. Inviragen is developing vaccines for dengue as well as hand, foot and mouth disease.
Takeda pays $35 million for Colo. vaccine developer
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan